Hypercoagulability in end-stage liver disease: Review of epidemiology, etiology, and management

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

In this review, we analyze the epidemiology of thromboses related to end-stage liver disease (ESLD), discuss causes of hypercoagulability, describe susceptible populations, and critically evaluate proposed prophylaxis and treatment of thromboses. Classically, ESLD has been regarded as a model for coagulopathy, and patients were deemed to be at high risk for bleeding complications. Patients with ESLD are not auto-anticoagulated, and they do not have a lower risk of portal vein thrombosis, intracardiac thrombus formation, pulmonary embolism or hepatic artery thrombosis. Though the cause of hypercoagulability is multifactorial, endothelial dysfunction likely plays a central role for all patients with ESLD. Some subpopulations, such as patients with nonalcoholic steatohepatitis and autoimmune conditions, are at increased risk of thrombotic events as are patients of Hispanic ethnicity. The science behind prophylaxis of different types of clotting and treatment of thromboses is developing rapidly. A number of medications, including low molecular weight heparin, unfractionated heparin, aspirin, vitamin K antagonists, and direct oral anticoagulants can be used, but clear guidelines are lacking. Acute intraoperative clotting can be associated with high mortality. Routine use of transesophageal echocardiography can be helpful in early recognition and treatment of intraoperative thrombosis. Heparin should be reserved for cases of intracardiac thrombus/pulmonary embolism without hemodynamic instability. In unstable patients, low dose of recombinant tissue plasminogen activator can be used. In this new era of heightened awareness of thrombotic events in ESLD patients, prospective randomized trials are urgently needed to best guide clinical practice.

Original languageEnglish (US)
Article numbere401
JournalTransplantation Direct
Volume4
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

End Stage Liver Disease
Thrombophilia
Epidemiology
Thrombosis
Pulmonary Embolism
Heparin
Vitamin K
Hepatic Artery
Low Molecular Weight Heparin
Transesophageal Echocardiography
Tissue Plasminogen Activator
Portal Vein
Hispanic Americans
Anticoagulants
Pulmonary Artery
Aspirin
Therapeutics
Hemodynamics
Guidelines
Hemorrhage

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

@article{7fa1e7d0d5da48bf83a0b842326809a6,
title = "Hypercoagulability in end-stage liver disease: Review of epidemiology, etiology, and management",
abstract = "In this review, we analyze the epidemiology of thromboses related to end-stage liver disease (ESLD), discuss causes of hypercoagulability, describe susceptible populations, and critically evaluate proposed prophylaxis and treatment of thromboses. Classically, ESLD has been regarded as a model for coagulopathy, and patients were deemed to be at high risk for bleeding complications. Patients with ESLD are not auto-anticoagulated, and they do not have a lower risk of portal vein thrombosis, intracardiac thrombus formation, pulmonary embolism or hepatic artery thrombosis. Though the cause of hypercoagulability is multifactorial, endothelial dysfunction likely plays a central role for all patients with ESLD. Some subpopulations, such as patients with nonalcoholic steatohepatitis and autoimmune conditions, are at increased risk of thrombotic events as are patients of Hispanic ethnicity. The science behind prophylaxis of different types of clotting and treatment of thromboses is developing rapidly. A number of medications, including low molecular weight heparin, unfractionated heparin, aspirin, vitamin K antagonists, and direct oral anticoagulants can be used, but clear guidelines are lacking. Acute intraoperative clotting can be associated with high mortality. Routine use of transesophageal echocardiography can be helpful in early recognition and treatment of intraoperative thrombosis. Heparin should be reserved for cases of intracardiac thrombus/pulmonary embolism without hemodynamic instability. In unstable patients, low dose of recombinant tissue plasminogen activator can be used. In this new era of heightened awareness of thrombotic events in ESLD patients, prospective randomized trials are urgently needed to best guide clinical practice.",
author = "Thomas Verbeek and Jonathan Stine and Saner, {Fuat H.} and Dmitri Bezinover",
year = "2018",
month = "11",
day = "1",
doi = "10.1097/TXD.0000000000000843",
language = "English (US)",
volume = "4",
journal = "Transplantation Direct",
issn = "2373-8731",
publisher = "Wolters Kluwer Health",
number = "11",

}

Hypercoagulability in end-stage liver disease : Review of epidemiology, etiology, and management. / Verbeek, Thomas; Stine, Jonathan; Saner, Fuat H.; Bezinover, Dmitri.

In: Transplantation Direct, Vol. 4, No. 11, e401, 01.11.2018.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Hypercoagulability in end-stage liver disease

T2 - Review of epidemiology, etiology, and management

AU - Verbeek, Thomas

AU - Stine, Jonathan

AU - Saner, Fuat H.

AU - Bezinover, Dmitri

PY - 2018/11/1

Y1 - 2018/11/1

N2 - In this review, we analyze the epidemiology of thromboses related to end-stage liver disease (ESLD), discuss causes of hypercoagulability, describe susceptible populations, and critically evaluate proposed prophylaxis and treatment of thromboses. Classically, ESLD has been regarded as a model for coagulopathy, and patients were deemed to be at high risk for bleeding complications. Patients with ESLD are not auto-anticoagulated, and they do not have a lower risk of portal vein thrombosis, intracardiac thrombus formation, pulmonary embolism or hepatic artery thrombosis. Though the cause of hypercoagulability is multifactorial, endothelial dysfunction likely plays a central role for all patients with ESLD. Some subpopulations, such as patients with nonalcoholic steatohepatitis and autoimmune conditions, are at increased risk of thrombotic events as are patients of Hispanic ethnicity. The science behind prophylaxis of different types of clotting and treatment of thromboses is developing rapidly. A number of medications, including low molecular weight heparin, unfractionated heparin, aspirin, vitamin K antagonists, and direct oral anticoagulants can be used, but clear guidelines are lacking. Acute intraoperative clotting can be associated with high mortality. Routine use of transesophageal echocardiography can be helpful in early recognition and treatment of intraoperative thrombosis. Heparin should be reserved for cases of intracardiac thrombus/pulmonary embolism without hemodynamic instability. In unstable patients, low dose of recombinant tissue plasminogen activator can be used. In this new era of heightened awareness of thrombotic events in ESLD patients, prospective randomized trials are urgently needed to best guide clinical practice.

AB - In this review, we analyze the epidemiology of thromboses related to end-stage liver disease (ESLD), discuss causes of hypercoagulability, describe susceptible populations, and critically evaluate proposed prophylaxis and treatment of thromboses. Classically, ESLD has been regarded as a model for coagulopathy, and patients were deemed to be at high risk for bleeding complications. Patients with ESLD are not auto-anticoagulated, and they do not have a lower risk of portal vein thrombosis, intracardiac thrombus formation, pulmonary embolism or hepatic artery thrombosis. Though the cause of hypercoagulability is multifactorial, endothelial dysfunction likely plays a central role for all patients with ESLD. Some subpopulations, such as patients with nonalcoholic steatohepatitis and autoimmune conditions, are at increased risk of thrombotic events as are patients of Hispanic ethnicity. The science behind prophylaxis of different types of clotting and treatment of thromboses is developing rapidly. A number of medications, including low molecular weight heparin, unfractionated heparin, aspirin, vitamin K antagonists, and direct oral anticoagulants can be used, but clear guidelines are lacking. Acute intraoperative clotting can be associated with high mortality. Routine use of transesophageal echocardiography can be helpful in early recognition and treatment of intraoperative thrombosis. Heparin should be reserved for cases of intracardiac thrombus/pulmonary embolism without hemodynamic instability. In unstable patients, low dose of recombinant tissue plasminogen activator can be used. In this new era of heightened awareness of thrombotic events in ESLD patients, prospective randomized trials are urgently needed to best guide clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=85060307406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060307406&partnerID=8YFLogxK

U2 - 10.1097/TXD.0000000000000843

DO - 10.1097/TXD.0000000000000843

M3 - Review article

C2 - 30534594

AN - SCOPUS:85060307406

VL - 4

JO - Transplantation Direct

JF - Transplantation Direct

SN - 2373-8731

IS - 11

M1 - e401

ER -